Clinicopathological characteristics of included PVRL patients
| Vitreous no. . | Age (y) . | Sex . | PCNSL . | Vitreous collection procedure . | Prev. intraocular surgery . | Syst. prev. GCs . | Interval since syst. GCs (d) . | Top. GCs . | Interval since top. GCs (d) . | AC cells . | Vitreous haze . | CME by FLA . | CME by OCT . | PVRL confirmation . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 63 | F | Yes | 23G VTX | None | No | — | No | — | 1+ | 3+ | None | None | IH |
| 2 | 67 | M | Yes | 23G VTX | None | No | — | No | — | 0 | 2+ | None | None | IH |
| 3 | 51 | M | Yes | 23G VTX | None | Yes | 7 | No | — | 0 | 3+ | None | None | IH + IgH-PCR |
| 4 | 78 | M | Yes | 23G VTX | None | No | — | No | — | 0 | 3+ | Not done | None | IH |
| 5 | 74 | M | Yes | 23G VTX | None | No | — | No | — | 0 | 2+ | Not done | Yes | IH + IgH-PCR |
| 6 | 53 | F | Yes | 23G VTX | None | No | — | No | — | 0 | 3+ | Not done | Not done | IH + IgH-PCR |
| 7 | 69 | F | Yes | 23G VTX | None | No | No | 0 | Hemorrhage | Not possible | Not possible | IH | ||
| 8 | 42 | F | No | 20G VTX, chorioretinal biopsy | VTX | Yes | 7 | Yes | 7 | 0.5+ | 2+ | None | None | IH |
| 9 | 60 | F | Yes | 23G VTX | None | Yes | 19 | Yes | 19 | 0 | 2+ | None | Not done | IH |
| 10 | 67 | F | Yes | 23G VTX | Cataract surgery 3 months ago | No | — | No | — | 1+ | 2+ | None | Not done | IH |
| Vitreous no. . | Age (y) . | Sex . | PCNSL . | Vitreous collection procedure . | Prev. intraocular surgery . | Syst. prev. GCs . | Interval since syst. GCs (d) . | Top. GCs . | Interval since top. GCs (d) . | AC cells . | Vitreous haze . | CME by FLA . | CME by OCT . | PVRL confirmation . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 63 | F | Yes | 23G VTX | None | No | — | No | — | 1+ | 3+ | None | None | IH |
| 2 | 67 | M | Yes | 23G VTX | None | No | — | No | — | 0 | 2+ | None | None | IH |
| 3 | 51 | M | Yes | 23G VTX | None | Yes | 7 | No | — | 0 | 3+ | None | None | IH + IgH-PCR |
| 4 | 78 | M | Yes | 23G VTX | None | No | — | No | — | 0 | 3+ | Not done | None | IH |
| 5 | 74 | M | Yes | 23G VTX | None | No | — | No | — | 0 | 2+ | Not done | Yes | IH + IgH-PCR |
| 6 | 53 | F | Yes | 23G VTX | None | No | — | No | — | 0 | 3+ | Not done | Not done | IH + IgH-PCR |
| 7 | 69 | F | Yes | 23G VTX | None | No | No | 0 | Hemorrhage | Not possible | Not possible | IH | ||
| 8 | 42 | F | No | 20G VTX, chorioretinal biopsy | VTX | Yes | 7 | Yes | 7 | 0.5+ | 2+ | None | None | IH |
| 9 | 60 | F | Yes | 23G VTX | None | Yes | 19 | Yes | 19 | 0 | 2+ | None | Not done | IH |
| 10 | 67 | F | Yes | 23G VTX | Cataract surgery 3 months ago | No | — | No | — | 1+ | 2+ | None | Not done | IH |
Biodata of all PVRL patients (Bochum/Germany: 5 PVRL specimens; Münster/Germany: 4 PVRL specimens; Mulhouse/France: 1 PVRL specimen) include age, sex, presence/absence of PCNSL, HIV status, biopsy method, previous cortisone therapy, and relevant clinical signs. All PVRL cases were diagnosed on the basis of morphology and immunoprofiling in the ocular oncology reference centers in Liverpool/United Kingdom, Lübeck/Germany, and Mulhouse/France. For 3 specimens, additional IgH-PCR was performed.
AC, anterior chamber; CME, cystoid macular edema; FLA, fluorescein angiography; GCs, glucocorticoids; IH, immunohistology; OCT, optical coherence topography; prev., previous; syst., systemic; top., topical; VTX, vitrectomy.